Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
Sayan Koley/LinkedIn
Jun 7, 2026, 05:50

Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment

Sayan Koley, Application Specialist at Imperial Biotek, shared a post on LinkedIn:

”Lupus Anticoagulant: A Key Marker in Thrombosis Risk Assessment

Despite its name, Lupus Anticoagulant (LA) is not an anticoagulant in the body.

It is an autoantibody that interferes with phospholipid-dependent coagulation tests and is strongly associated with an increased risk of thrombosis.

Why is it important?  Associated with venous and arterial thrombosis

  • Plays a major role in the diagnosis of Antiphospholipid Syndrome
  • Linked to recurrent pregnancy complications
  • Critical for patient risk assessment and treatment planning

Laboratory Detection

  • Screening Tests: dRVVT, LA-sensitive aPTT
  • Mixing Studies
  •  Confirmatory Tests with excess phospholipid
  • Persistent positivity after 12 weeks supports
    clinical significance

Key Message:

A prolonged clotting time in vitro does not necessarily indicate a bleeding risk.

In many cases, Lupus Anticoagulant is associated with an increased tendency to form blood clots.

Accurate testing, proper interpretation, and close collaboration between clinicians and laboratory professionals are essential for optimal patient care.”

Sayan Koley: Lupus Anticoagulant - A Key Marker in Thrombosis Risk Assessment

Stay updated with Hemostasis Today.

Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Sayan Koley thrombosis
NewsFeed